JMP Securities Maintains Market Outperform on Haemonetics, Raises Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst David Turkaly maintains a Market Outperform rating on Haemonetics (NYSE:HAE), raising the price target from $115 to $125.
May 10, 2024 | 4:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has raised the price target for Haemonetics from $115 to $125 while maintaining a Market Outperform rating.
The increase in price target by JMP Securities suggests a positive outlook on Haemonetics' stock, likely due to strong company performance or favorable market conditions. This analyst action can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100